Eli Lilly’s new research suggests its medication Zepbound may be more effective for weight loss than Novo Nordisk’s Wegovy. A preliminary study found that patients taking Zepbound lost more weight over a 72-week treatment period compared to those on Wegovy.
Zepbound, which contains tirzepatide, has been shown to be more effective in helping people lose weight faster and for longer periods of time than Wegovy. The medication works by mimicking gut hormones that signal the brain when we’re full, reducing hunger and increasing feelings of fullness.
One patient, Barbara Strecker-Gaudreau, reported significant weight loss and improvements in her overall health after switching to Zepbound. She lost over 60 pounds and experienced a reduction in blood pressure and heart rate.
Her daughter, Alexis, also tried Zepbound and saw similar results, losing 10 pounds in the first month of treatment. Experts note that while these medications can be effective, lifestyle changes such as diet and exercise are also crucial for sustainable weight loss.
The study’s findings have been met with skepticism from Novo Nordisk, which claims Wegovy is the only obesity medicine proven to reduce the risk of major cardiovascular events. However, Eli Lilly argues its research shows Zepbound has significant benefits for weight loss. As with all medications, side effects such as nausea and vomiting are possible, and experts caution that lifestyle interventions should be used in conjunction with these treatments.
Both Zepbound and Wegovy are antidiabetic medications, mimicking gut hormones to regulate appetite and metabolism. The complexity of weight regulation means that targeting one pathway is often not enough; two or more pathways need to be addressed for optimal results.
Source: https://abcnews.go.com/Health/zepbound-users-discuss-weight-loss-after-preliminary-research/story?id=116449668